Table 1 Baseline characteristics of VITAL-T2D participants randomized to vitamin D vs. placebo
VITAL-T2D Cohort | Placebo (n = 11,158) | Vitamin D (n = 11,062) |
|---|---|---|
Baseline characteristics, n (%) | ||
Age, mean (SD), yr | 67.2 (7.1) | 67.2 (7.1) |
<65.0 | 4214 (37.8) | 4173 (37.7) |
≥65.0 | 6944 (62.2) | 6889 (62.3) |
Female sexa | 5615 (50.3) | 5600 (50.6) |
Body mass indexb, mean (SD), kg/m2 | 27.5 (5.3) | 27.5 (5.2) |
<25.0 | 3739 (34.3) | 3657 (33.8) |
25.0 to 30.0 | 4499 (41.2) | 4460 (41.2) |
≥30.0 | 2672 (24.5) | 2703 (25.0) |
Race/ethnicitya | ||
Non-Hispanic White | 8073 (72.4) | 8048 (72.8) |
Black | 1947 (17.4) | 1905 (17.2) |
Hispanic | 397 (3.6) | 406 (3.7) |
Asian or Pacific Islander | 160 (1.4) | 146 (1.3) |
Native American or Alaskan Native | 98 (0.9) | 94 (0.8) |
Other or unknown | 230 (2.1) | 216 (2.0) |
US region | ||
West | 2620 (23.5) | 2542 (23.0) |
Midwest | 2357 (21.1) | 2350 (21.2) |
Southeast | 3075 (27.6) | 3044 (27.5) |
Northeast | 3105 (27.8) | 3126 (28.3) |
Hypertension treated with medication | 5293 (47.4) | 5147 (46.5) |
Cholesterol-lowering medication use | 3633 (32.6) | 3636 (32.9) |
Vitamin D supplement use ≤800 ID/dc | 4880 (43.7) | 4845 (43.8) |
Serum 25-hydoxyvitamin D, median (IQR), ng/ml | 31 (25—37) | 31 (25—37) |
<20 ng/ml | 838 (12.2) | 765 (11.3) |
Randomized to active omega-3 group | 5572 (49.9) | 5519 (49.9) |
